Gene · 6139
Papers2,197
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
21 to 40 of 2,197
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| ACT001 synergizes with temozolomide-based chemoradiotherapy to cure refractory glioblastoma by targeting TNF-CXCL10-CD8+ T-cell immunity. | Front Pharmacol | 2026 | 41769685 | PubTator, text mining | PubMed |
| Redefining the immune microenvironment of gliomas in the era of single-cell genomics. | Neurooncol Adv | 2026 | 41769417 | PubTator, text mining | PubMed |
| Decoding the role of RPL38 in lung adenocarcinoma: a multi-omics approach. | Front Immunol | 2026 | 41766901 | PubTator, text mining | PubMed |
| Cytokines Associated with Activation of CD4+CD25+Foxp3+ T Regulatory Cells. | Int J Mol Sci | 2026 | 41752221 | PubTator, text mining | PubMed |
| The Fibro-Immune Landscape Across Organs: A Single-Cell Comparative Study of Human Fibrotic Diseases. | Int J Mol Sci | 2026 | 41752153 | PubTator, text mining | PubMed |
| Mucosal Remodeling in Chronic Rhinosinusitis with Nasal Polyps: The Role of Innate Lymphoid Cells and Reprogramming Under IL-4Rα Blockade. | Int J Mol Sci | 2026 | 41752128 | PubTator, text mining | PubMed |
| NKGD2 Ligands (NKG2DLs) in Breast Cancer: In Silico Analysis and Narrative Review. | Int J Mol Sci | 2026 | 41751981 | PubTator, text mining | PubMed |
| Metabolic Messengers: Extracellular Vesicles as Central Mediators of Metabolic Reprogramming in Renal Cell Cancer. | Biomedicines | 2026 | 41751181 | PubTator, text mining | PubMed |
| The Cross-Knit Between Immune Cells and Thyroid Function in Autoimmune Thyroid Disorders: What We Can Learn from Inborn Errors of Immunity. | Children (Basel) | 2026 | 41749525 | PubTator, text mining | PubMed |
| Cuproptosis-related gene signatures define immune subtypes and predict prognosis in gastric cancer. | Front Mol Biosci | 2026 | 41737832 | PubTator, text mining | PubMed |
| A mixed inflammatory peripheral signature defines clinical outcomes in a phase II trial combining pembrolizumab with paclitaxel and carboplatin in melanoma. | Oncoimmunology | 2026 | 41732954 | PubTator, text mining | PubMed |
| Blinatumomab-driven T-cell activation in αβ and γδ T-cell subsets: insights from in vitro assays. | Front Immunol | 2026 | 41727470 | PubTator, text mining | PubMed |
| UNC93B1 promotes pancreatic cancer progression through modulation of cGAS-STING signaling. | Front Immunol | 2026 | 41716413 | PubTator, text mining | PubMed |
| m6A demethylase-driven reprogramming of leukemia-associated macrophages predicts improved outcomes in acute myeloid leukemia. | Front Immunol | 2026 | 41710900 | PubTator, text mining | PubMed |
| Single-Cell RNAseq Identifies Heterogeneity in Myoblasts From Older Adults With Differences Related to Muscle Mass and Function. | J Cachexia Sarcopenia Muscle | 2026 | 41703779 | PubTator, text mining | PubMed |
| Uridine diphosphate drives myeloid differentiation and functional reprogramming through dynamic transcriptional network. | Front Immunol | 2026 | 41694396 | PubTator, text mining | PubMed |
| The ER membrane protein complex acts as a chaperone to promote the biogenesis of multi-bundle membrane proteins. | bioRxiv | 2026 | 41648177 | PubTator, text mining | PubMed |
| Virus-like particles based on plant viruses and bacteriophages: emerging strategies for the delivery of nucleic acid therapeutics. | Chem Sci | 2026 | 41647042 | PubTator, text mining | PubMed |
| Development of a unified mass cytometry assay integrating activation-induced markers (AIMs) and cytokine profiling for high-throughput assessment of antigen-specific T cell responses. | Hum Vaccin Immunother | 2026 | 41614453 | PubTator, text mining | PubMed |
| CXCR4-modification enhances CAR-T efficacy by improving tumor tracking and bone marrow homing in B-cell malignancies. | Signal Transduct Target Ther | 2026 | 41605906 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6139/papers?page=2